2025 年胃癌转化研究进展:整合生物标志物、新型疗法与微环境重塑
Translational advances in gastric cancer: integrating biomarkers, novel therapies, and microenvironment remodeling in 2025.
胃癌(GC)仍然是全球主要的健康负担,总体预后不理想,这在很大程度上归因于其显著的异质性、晚期诊断和治疗耐药。
49.6分
★★★☆☆
FRONTIER PAPERS
Translational advances in gastric cancer: integrating biomarkers, novel therapies, and microenvironment remodeling in 2025.
胃癌(GC)仍然是全球主要的健康负担,总体预后不理想,这在很大程度上归因于其显著的异质性、晚期诊断和治疗耐药。
Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
尽管嵌合抗原受体(CAR)-T细胞疗法在血液系统恶性肿瘤中已成功应用,但在实体瘤中的治疗效果仍不理想,这主要归因于高度免疫抑制的肿瘤微环境和特异性肿瘤抗原密度低。
Evaluation of Synergic Effects of Molybdenum Disulfide Treatment and Near-Infrared Radiation on Human Mesenchymal Stem Cells.
研究结果提示,MoS2 的抗癌特性在 NIR 照射条件下得到增强。
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。